VECTOR CORE FACILITY

向量核心设施(VCF)已经并将继续作为一个重要的共享设施服务于 UPCI的研究人员通过向UPCI提供数百种病毒和非病毒载体和试剂 成员，特别是用于癌症基因治疗的。尽管超过50%的这一使用 共享设施由UPCI成员提供，请求的CCSG支持仅约占总数的15% 设施的预算。VCF在UPCI的框架内作为动态资源运行， 开发新的载体并提供最先进的病毒和非病毒载体技术。少校 VCF的重点一直是使用腺病毒和逆转录病毒载体进行基因转导。 该设施还具有生产腺相关病毒和用于基因的dna质粒的能力。 送货。除了载体，该设施还提供细胞系、病毒、包装线、质粒和 方案，以及向个人提供使用病毒和非病毒载体的技术援助和培训 用于基因转移。为了应对研究需求的增长，VCF在过去一年里扩大了 其重点是包括表达shRNA和cDNA的慢病毒载体，以帮助基因发现的研究， 药物开发和靶向验证，并向UPCI成员提供这方面的专业知识和试剂 利用慢病毒载体参与基础科学研究。目前，VCF提供的包括高-和 低滴度HIV和FIV慢病毒、荧光蛋白表达和shRNA存量病毒的制备 从人类和小鼠基因特异性文库中表达，设计和开发慢病毒 用于细胞研究和转基因小鼠生产、细胞转导和 鉴定(稳定细胞系的建立和qRT-PCR分析)和慢病毒滴定和 测试复制能力。 病媒核心基金的具体目标是： 1.为UPCI调查人员提供表达shRNA或特定基因的病毒和非病毒载体 对于他们提出的实验来说，这是最合适和最有效的。 2.开发改进的病毒和非病毒载体，以更高和/或更高的效率进行基因转移 调控的基因表达。 3.协助开发新的、最先进的高效基因传递方法。 4.利用病毒和非病毒，为基因治疗项目提供技术援助和方案 基因输送系统。

The Vector Core Facility (VCF) has served, and will continue to serve, as an important shared facility for UPCI researchers by providing many hundreds of viral and non-viral vectors and reagents to UPCI members, particularly for use in cancer gene therapy. Although greater than 50% of the usage of this shared facility is by UPCI members, requested CCSG support is only approximately 15% of the total budget of the facility. The VCF functions within the framework of the UPCI as a dynamic resource that develops novel vectors and provides state-of-the-art viral and non-viral vector technology. The major emphasis of the VCF has been on the utilization of adenoviral and retroviral vectors for gene transduction. This facility also has the capability to produce adeno-associated viruses and DNA plasmids for gene delivery. In addition to vectors, the facility also provides cell lines, viruses, packaging lines, plasmids, and protocols, as well as technical assistance and training to individuals in the use of viral and non-viral vectors for gene transfer. In response to a growth in research demand, over the last year the VCF has expanded its focus to include lentiviral vectors for expression of shRNA and cDNA to aid in studies of gene-discovery, drug development and target validation, and to provide this expertise and reagents to UPCI members involved in basic science research using lentiviral vectors. Currently the VCF provides include high- and low-titer HIV and FIV lentivirus, preparation of stock viruses for fluorescent protein expression and shRNA expression from a library specific to human and mouse genes, design and development of lentiviruses for cDNA expression for cell-based studies and transgenic mouse production, cell transduction & characterization (development of stable cell lines and analysis by qRT-PCR) and lentiviral titering and testing for replication competence. The specific aims of the Vector Core Facility are to: 1. Provide UPCI investigators with viral and non-viral vectors that express shRNA or the specific gene of interest and that are most appropriate and efficacious for their proposed experiments. 2. Develop improved viral and non-viral vectors for more efficient gene transfer with higher and/or regulated gene expression. 3. Assist in the development of new, state-of-the-art methods for efficient gene delivery. 4. Provide technical assistance and protocols for gene therapy projects, making use of viral and non-viral gene delivery systems.